Bladder Cancer
Bladder cancer is the fourth most common cancer among males in the US and due to its prevalence among the over 65s, diagnoses are set to increase in ageing populations worldwide. Reports in the Bladder Cancer section cover a variety of areas, such as the latest R&D and clinical trials taking place in universities, hospitals and other research centres around the world. Explore epidemiology, unmet needs, drug development (cytotoxic, immunotherapy agents, etc.), supply & demand, business development
strategies, licensing and partnership opportunities, and the activities of key industry players such as Bristol-Myers Squibb, Spectrum Pharmaceuticals, Bioniche Life Sciences, Endo Pharmaceuticals, Eli Lilly and Sanofi-Aventis.
Show Less
Read more
Bladder Cancer – Executive Market Summary 2013
The Bladder Cancer Executive Market Summary 2013 provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide,...
May
2013
FROM
EUR 1,065USD 995GBP 605AUD 1,449JPY 122,093SEK 8 586CHF 1'429CAD 1,330
Bladder Cancer Drug Pipeline Update 2013
According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate...
April
2013
EUR 999USD 1,306GBP 842AUD 1,390JPY 127,913SEK 8 649CHF 1'229CAD 1,358
Global Bladder Cancer Pipeline Capsule - 2013
Fore Pharma’s latest report ‘Global Bladder Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global bladder cancer market. It covers...
April
2013
FROM
EUR 528USD 690GBP 445AUD 734JPY 67,575SEK 4 569CHF 649CAD 717
09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012 All companies include technology, market(s), key...
September
2012
FROM
EUR 152USD 199GBP 128AUD 212JPY 19,489SEK 1 318CHF 187CAD 207
06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 39 emerging medical technology companies that have been identified by LSI's in-house research team in June 2012 All companies include technology, market(s), key executive,...
June
2012
FROM
EUR 302USD 395GBP 255AUD 420JPY 38,684SEK 2 616CHF 372CAD 411
Bladder Cancer – Executive Market Summary 2011
Executive Market Summaries were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format These reports are prepared by the senior market...
May
2012
FROM
EUR 1,065USD 995GBP 605AUD 1,449JPY 122,093SEK 8 586CHF 1'429CAD 1,330
05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 41 emerging medical technology companies that have been identified by LSI's in-house research team in May 2012 All companies include technology, market(s), key executive,...
May
2012
FROM
EUR 302USD 395GBP 255AUD 420JPY 38,684SEK 2 616CHF 372CAD 411
04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 37 emerging medical technology companies that have been identified by LSI's in-house research team in April 2012 All companies include technology, market(s), key executive,...
April
2012
FROM
EUR 302USD 395GBP 255AUD 420JPY 38,684SEK 2 616CHF 372CAD 411
03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 61 emerging medical technology companies that have been identified by LSI's in-house research team in March 2012 All companies include technology, market(s), key executive,...
March
2012
FROM
EUR 302USD 395GBP 255AUD 420JPY 38,684SEK 2 616CHF 372CAD 411
02 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 43 emerging medical technology companies that have been identified by LSI's in-house research team in February 2012 All companies include technology, market(s), key executive,...
February
2012
FROM
EUR 302USD 395GBP 255AUD 420JPY 38,684SEK 2 616CHF 372CAD 411
Global Bladder Cancer Drug Pipeline Capsule - 2012
Fore Pharma’s latest report ‘Global Bladder Cancer Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global bladder cancer drug market. It covers...
January
2012
FROM
EUR 321USD 420GBP 271AUD 447JPY 41,133SEK 2 781CHF 395CAD 437
01 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities
This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012 All companies include technology, market(s), key executive,...
January
2012
FROM
EUR 302USD 395GBP 255AUD 420JPY 38,684SEK 2 616CHF 372CAD 411
Niche Markets and Rare Diseases: Bladder Cancer
The bladder is the fourth most common tumor site among all tumors that can afflict both genders However, because of its very high risk of recurrence and its frequent presentation as multiple tumors...
December
2011
EUR 7,649USD 10,000GBP 6,446AUD 10,641JPY 979,353SEK 66 216CHF 9'410CAD 10,398
Bladder Cancer Global Clinical Trials Review, H2, 2011
Summary
GlobalData's clinical trial report, “Bladder Cancer Global Clinical Trials Review, H2, 2011" provides data on the Bladder Cancer clinical...
August
2011
FROM
EUR 765USD 1,000GBP 645AUD 1,064JPY 97,935SEK 6 622CHF 941CAD 1,040
Global Bladder Cancer Drug Pipeline Capsule - 2011
Fore Pharma's latest report ‘Global Bladder Cancer Drug Pipeline Capsule – 2011' is an outline of all the key research and development (R&D) activities of the global bladder cancer drug market It covers...
August
2011
FROM
EUR 283USD 370GBP 238AUD 394JPY 36,236SEK 2 450CHF 348CAD 385
2011 Global Markets for External Radiation Therapy
2011 Global Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...
May
2011
FROM
EUR 4,972USD 6,500GBP 4,190AUD 6,917JPY 636,580SEK 43 041CHF 6'116CAD 6,759
2011 U.S. Markets for External Radiation Therapy
2011 U S Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data -...
May
2011
FROM
EUR 2,983USD 3,900GBP 2,514AUD 4,150JPY 381,948SEK 25 824CHF 3'670CAD 4,055
2011 O.U.S. Markets For External Radiation Therapy
2011 O U S Markets For External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...
May
2011
FROM
EUR 2,983USD 3,900GBP 2,514AUD 4,150JPY 381,948SEK 25 824CHF 3'670CAD 4,055
Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 Summary GlobalData, the industry analysis specialist, has released its new report, “Bladder Cancer - Global Drug...
April
2011
FROM
EUR 3,824USD 5,000GBP 3,223AUD 5,320JPY 489,677SEK 33 108CHF 4'705CAD 5,199
Bladder Cancer Therapeutics - Global Strategic Business Report
This report analyzes the worldwide markets for Bladder Cancer Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual estimates...
October
2010
FROM
EUR 3,496USD 3,950GBP 2,330AUD 5,462JPY 473,679SEK 31 073CHF 5'202CAD 5,066
